文献速递临床试验与 GCP基础与转化研究

恢复期血浆对重症COVID-19患者无器官支持天数的影响:一项随机临床试验

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

REMAP-CAP平台试验在4国129个中心随机2011例重症COVID-19成人,比较2单位高滴度ABO相容恢复期血浆与无血浆。血浆组无器官支持天数中位数0天 vs 3天,住院死亡率37.3% vs 38.4%,调整OR 0.97(95%可信区间0.83-1.15),无效性后验概率99.4%,试验因无效提前停止。

要点

  • 重症COVID-19成人使用2单位高滴度恢复期血浆未改善无器官支持天数。
  • 住院死亡率血浆组37.3%、无血浆组38.4%,调整OR 0.97(95%可信区间0.83-1.15)。
  • 无效性后验概率99.4%,试验达到预设无效标准后停止血浆干预。

核心结论

  • 重症COVID-19成人使用2单位高滴度ABO相容恢复期血浆改善无器官支持天数的可能性低。

研究设计与样本

  • REMAP-CAP为正在进行的随机、嵌入、多因素、自适应平台试验,纳入疑似或确诊COVID-19成人。
  • 2020年3月9日至2021年1月18日,4国129个中心共2011例重症成人随机至高滴度ABO相容恢复期血浆组(n=1084)或无恢复期血浆组(n=916)。
  • 主要终点为第21天无器官支持天数(范围-1至21天,死亡记为-1天),采用调整贝叶斯累积逻辑模型分析。

主要发现

  • 血浆组无器官支持天数中位数0天(IQR -1至16),无血浆组3天(IQR -1至16)。
  • 住院死亡率血浆组37.3%(401/1075),无血浆组38.4%(347/904)。
  • 调整OR 0.97(95%可信区间0.83-1.15),无效性后验概率99.4%。
  • 严重不良事件血浆组3.0%(32/1075),无血浆组1.3%(12/905)。

关键数值与推荐

  • 优效性判定阈值为OR>1的后验概率>99%,无效性判定阈值为OR<1.2的后验概率>95%。
  • OR>1代表生存改善、无器官支持天数增加或两者兼有。

临床怎么用

  • 不推荐对重症COVID-19成人常规使用2单位高滴度ABO相容恢复期血浆以改善无器官支持天数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive. OBJECTIVE: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021. INTERVENTIONS: The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916). MAIN OUTCOMES AND MEASURES: The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events. RESULTS: Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11 secondary outcomes. Serious adverse events were reported in 3.0% (32/1075) of participants in the convalescent plasma group and in 1.3% (12/905) of participants in the no convalescent plasma group. CONCLUSIONS AND RELEVANCE: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 34606578. doi:10.1001/jama.2021.18178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。